Investigational drug · Phase 3
Sinovac PCV13
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pneumococcal Infectious Diseases, Pneumococcal Infectious Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: May 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Sinovac PCV13"
First trial start
2024
Oct 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sinovac PCV13", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Infectious Diseases
- Pneumococcal Infectious Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Sinovac PCV13" as an intervention, largest first.
- Clinical Trial of 13-Valent Pneumococcal Conjugate VaccinePivotal-lookingRecruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT06617715 · 3,080 participants (planned) · Start Oct 23, 2024 · Primary completion May 12, 2026
Drug: Sinovac PCV13; Prevnar® · For: Pneumococcal Infectious Disease
Sites: Zhengzhou, China
- A Lot-to-Lot Consistency Clinical Trial of PCV13Pivotal-lookingNot yet recruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT07832500 · 1,125 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Drug: Sinovac PCV13 lot 1; Sinovac PCV13 lot 2 and 1 more · For: Pneumococcal Infectious Diseases
Sites: Ürümqi, China
- Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Pivotal-lookingNot yet recruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT07593924 · 500 participants (planned) · Start May 2026 · Primary completion Jul 2027
Drug: Sinovac PCV13; Prevenar 13™ · For: Pneumococcal Infectious Diseases
Sites: Imus, Philippines
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate VaccinePivotal-lookingCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT05092386 · 310 participants · Start Jan 3, 2023 · Primary completion May 26, 2024
Drug: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine; Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13) and 1 more · For: Pneumococcal Infections
Sites: Zhengzhou, China
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccinePivotal-lookingCompleted
Sinovac Research and Development Co., Ltd.Industry
NCT06183216 · 140 participants · Start Jan 4, 2024 · Primary completion Mar 26, 2025
Drug: Sinovac PCV13; PREVNAR 13 · For: Pneumococcal Infectious Disease
Sites: Dali, China
- Clinical Trial of PCV24 in Children Aged 2-17 YearsPivotal-lookingCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT06550830 · 119 participants · Start Sep 7, 2024 · Primary completion Jun 25, 2025
Drug: Sinovac PCV24 formulation 1; Sinovac PCV24 formulation 2 and 1 more · For: Pneumococcal Infectious Disease
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pneumococcal Infectious Diseases
- Prevenar 13Phase 31 trial
Sinovac Life Sciences Co., Ltd. · Pneumococcal Infectious Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.